Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROSHARES TRUST (ZBIO) Total Liabilities: 2023-2025

Historic Total Liabilities for Zenas BioPharma (ZBIO) over the last 2 years, with Sep 2025 value amounting to $125.6 million.

  • Zenas BioPharma's Total Liabilities rose 185.45% to $125.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $125.6 million, marking a year-over-year increase of 185.45%. This contributed to the annual value of $57.5 million for FY2024, which is 31.26% up from last year.
  • Per Zenas BioPharma's latest filing, its Total Liabilities stood at $125.6 million for Q3 2025, which was up 134.93% from $53.5 million recorded in Q2 2025.
  • In the past 5 years, Zenas BioPharma's Total Liabilities registered a high of $288.8 million during Q2 2024, and its lowest value of $43.8 million during Q4 2023.
  • In the last 3 years, Zenas BioPharma's Total Liabilities had a median value of $57.5 million in 2024 and averaged $124.1 million.
  • Over the last 5 years, Zenas BioPharma's Total Liabilities had its largest YoY gain of 185.45% in 2025, and its largest YoY loss of 81.49% in 2025.
  • Zenas BioPharma's Total Liabilities (Quarterly) stood at $43.8 million in 2023, then spiked by 31.26% to $57.5 million in 2024, then spiked by 185.45% to $125.6 million in 2025.
  • Its Total Liabilities was $125.6 million in Q3 2025, compared to $53.5 million in Q2 2025 and $49.4 million in Q1 2025.